Sun-Ranbaxy Merger Could Take Several Months Getting India Approval
This article was originally published in PharmAsia News
The $4 billion Sun Pharmaceutical Industries acquisition of Ranbaxy Laboratories from Daiichi Sankyo appears likely to take much longer than the average 30 days for approval in India because of the deal's complexity.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.